1. Home /
  2. Drug Approvals

Drug Approvals

3 Must Reads on the Market From TheStreet's Top Columnists

3 Must Reads on the Market From TheStreet's Top Columnists

Jim Cramer and our other experts discuss oil prices, bullish market signals and medical diagnostic plays.

Amgen, Novartis Clinch FDA Nod on Migraine Prevention Drug

Amgen, Novartis Clinch FDA Nod on Migraine Prevention Drug

Aimovig is the first treatment approved by the agency to prevent migraines by blocking the calcitonin gene-related peptide receptor.

Trump Administration Rolls Out Shaming as Drug Pricing Tool

Trump Administration Rolls Out Shaming as Drug Pricing Tool

When President Trump gave a speech on prescription drug pricing last week, many were disappointed pharmaceutical companies seemed to escape his wrath. The answer seems to be shame.

3 Cutting-Edge Biotech Stocks That Can Double in Value

3 Cutting-Edge Biotech Stocks That Can Double in Value

These three "strong buy" biotech stocks are primed for outsized growth in the next 12 months. Here's why.

It's Dumb to Think Legalizing Weed Is Still a Political Issue

It's Dumb to Think Legalizing Weed Is Still a Political Issue

What was once a red and blue issue has now attracted a growing set of proponents from both sides of the aisle. Here's what that could mean for regulation of legal cannabis in the U.S.

In Biopharma M&A, 'Where There's Real Innovation There's Someone Willing to Pay'

In Biopharma M&A, 'Where There's Real Innovation There's Someone Willing to Pay'

Deals in biopharma slowed in 2017 for the third consecutive year. According to Intec Pharma CEO Jeffrey Meckler, just because volume is down doesn't mean it's out.

Sarepta Hit With Call to Drop Duchenne Drug Costs

Sarepta Hit With Call to Drop Duchenne Drug Costs

The biopharmaceutical company, which won controversial FDA approval for a Duchenne Muscular Dystrophy drug, now confronts patient groups asking HHS to take its patents and drop the price of that drug.

Trump's Opioid Plan Gives Alkerme's Vivitrol Drug a Sales Boost

Trump's Opioid Plan Gives Alkerme's Vivitrol Drug a Sales Boost

Alkermes has spent money lobbying and donating to elected officials, and in the White House opioid plan, it seems to have paid off, as opioid blocker Vivitrol becomes part of prison protocol.

J&J Shares Off to Worst Start to a Year This Century: RBC Capital Markets

J&J Shares Off to Worst Start to a Year This Century: RBC Capital Markets

Johnson & Johnson may be down, but don't count it out.

5 Super Scary Health Care Statistics

5 Super Scary Health Care Statistics

The Oracle of Omaha, long with Wall Street titans Jamie Dimon and Jeff Bezos want to fix health care -- at least for their over 1 million employees.